A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Amplified Breast Cancer
Interventions: DRUG: Neratinib|DRUG: Capecitabine|DRUG: Loperamide
Sponsor: Puma Biotechnology, Inc.